Suscribirse

Phenotypic differences of chronic angiotensin II/phenylephrine infusion in C57BL/6J and C57BL/6N mouse strains - 21/05/25

Doi : 10.1016/j.acvd.2025.03.072 
Zhenyi Zhao 1, , Iman Momken 2, Mathias Mericskay 1
1 Inserm UMRS-1180 signalisation et physiopathologie cardiovasculaire, faculté de pharmacie, université Paris-Saclay, Orsay, France 
2 Inserm Carpat u1180, faculté de pharmacie, université Paris-Saclay, Châtenay-Malabry, France 

Corresponding author.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Summary

Introduction

Hypertension is present in 75% of patients suffering heart failure with preserved ejection fraction (HFpEF) patients while obesity is present in average in only 30–40%. Angiotensin II/phenylephrine (ANGII/PE) infusion in mice is a new model of HFpEF without obesity [1]. The C57BL/6J (B6J) and C57BL/6N (B6N) inbred substrains are frequently used to study pathological models. The metabolic phenotypic differences between B6J and BL6N are considered to be influenced by the nicotinamide nucleotide transhydrogenase (Nnt) gene, which is found only in B6J. Nnt is a key antioxidative enzyme based on its ability to regenerate NADPH from NADH.

Objective

We aim to compare the effects of ANG II/PE infusion on B6J and B6N mice.

Method

Male mice (8 week-old) were implanted with an osmotic minipump to allow continuous infusion of ANG II/PE for 21 days. Echocardiography was performed at 19/20 days. Cardiac hypertrophy and fibrosis were evaluated by histological methods and by qRT-PCR and Western blot. Mitochondrial respiration was assessed by oxygrqphy and NAD was quantified by the alcohol dehydrogenase cycling assay.

Results

Radial fractional shortening was preserved in B6J-ANGII/PE and LVEF (B-mode) was moderately reduced to 43 vs. 61% in control (saline) group, while both parameters were severely reduced in B6N mice. AngII/PE significantly increased E/A ratio in B6J that exhibited concentric hypertrophy, whereas B6N mice exhibited eccentric hypertrophy and A wave was not detected. Lung weight to tibia length ratio was increased in both strains. B6N mice showed more severe cardiac fibrosis and hypertrophy. Increased protein expression of Pparg coactivator 1 alpha (PGC-1α) and Sirtuin1 was observed with AngII/PE in B6N mice only. There was no significant difference in mitochondrial oxidative capacity and NAD levels between B6N and B6J mice and no impact of the treatment.

Conclusion

With AngII/PE infusion, B6J mice presented features of HF with mid-range EF while B6N mice developed HF with reduced ejection fraction (HFrEF). This new model provides an angle to study the divergent pathophysiological pathways of HFpEF vs HFrEF in the context of hypertension. Our future studies will also aim to identify the different molecular mechanisms of B6J and B6N mice under thispathological stimulation and explore biological sex differences.

El texto completo de este artículo está disponible en PDF.

Esquema


© 2025  Publicado por Elsevier Masson SAS.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 118 - N° 6-7S1

P. S207 - juin 2025 Regresar al número
Artículo precedente Artículo precedente
  • Distinct Ca2+ handling modulation in a rat model of right hypertrophy and dysfunction in response to mild or severe pulmonary artery constriction
  • Pauline Le Gourriérec, Kristelle El Jekmek, Angele Boet, Antoine Beauvais, David Montani, Olaf Mercier, Fabrice Antigny, Jessica Sabourin
| Artículo siguiente Artículo siguiente
  • Could cardiac rehabilitation be relevant for patients with end-stage heart failure treated by continuous IV dobutamine in destination therapy?
  • Charlotte Hulin-Delmotte, Nathalie Charlotte, Xavier Balaire, Aurélie Bardet

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.